Stay updated on Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of patients estimated to be enrolled in the Phase II trial of Pembrolizumab in Combination With Paclitaxel for Hormone Receptor-positive Metastatic Breast Cancer with High Tumor Mutational Burden.
    Difference
    0.1%
    Check dated 2024-06-06T14:22:19.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying that pre or postmenopausal women with stage IV hormone receptor-positive breast cancer are eligible. The criteria now also include specific health conditions, prior treatments, and other requirements such as age and performance status.
    Difference
    48%
    Check dated 2024-05-22T20:55:50.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:28:06.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.